1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Novartis commences tender offer to acquire Regulus Therapeutics

29 May 2025
Admin
News Article

Novartis commences tender offer to acquire Regulus Therapeutics

Novartis announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (Purchaser), has commenced a tender offer to acquire all of the outstanding shares of common stock (par value $0.001 per share) of Regulus Therapeutics Inc., a Delaware corporation.

The offer includes:

$7.00 in cash per Share, subject to any applicable withholding and without interest, and
One contingent value right (CVR) per Share, entitling the holder to receive an additional $7.00 in cash, contingent upon the achievement of a regulatory milestone.

Offer Documents and Merger Agreement

The offer is being made under the terms and subject to the conditions outlined in the:

Offer to Purchase, dated May 27, 2025
Letter of Transmittal
Agreement and Plan of Merger, dated April 29, 2025, among Novartis, Purchaser, and Regulus

Key Dates and Deadlines

Expiration Time

The offer will expire at one minute past 11:59 p.m. (New York City time) on June 24, 2025, unless extended or earlier terminated (the “Expiration Time”).

Extension Notifications

Any extension, delay, termination, or amendment of the Offer will be announced as promptly as possible. In the case of an extension, an announcement will be made no later than 9:00 a.m. Eastern time on the business day after the previously scheduled Expiration Time.

SEC Filings and Board Recommendation

Novartis SEC Filing

Novartis filed a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (SEC). This includes the Offer to Purchase, which outlines the full terms and conditions of the Offer.

Regulus SEC Filing and Recommendation

Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC. This filing includes a recommendation from Regulus’s Board of Directors urging stockholders to accept the Offer and tender their Shares.

Conditions of the Offer

Customary Regulatory and Tender Conditions

Purchaser’s obligation to buy validly tendered (and not withdrawn) Shares is subject to:

Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
At least one more Share than 50% of the total outstanding Shares being validly tendered and not withdrawn (including those already owned by Novartis, Purchaser, or their subsidiaries).

Support Services and Contact Information

Information Agent

Innisfree M&A Incorporated is acting as the Information Agent for Purchaser.

Depositary and Paying Agent

Computershare Trust Company, N.A. is serving as the Depositary and Paying Agent.

Contact Details for Stockholders

Stockholders with questions or in need of documents related to the Offer may contact Innisfree M&A Incorporated:

Toll-free (U.S./Canada): (877) 800-5186

International: +1 (412) 232-3651

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!